We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 207% below its sector, cheaper than its peers on earnings.
Sunflower Pharmaceutical Group Co., Ltd. is a Chinese enterprise dedicated to the comprehensive process of traditional Chinese medicine (TCM), covering everything from research and development to production and market distribution within China. The company's product range also extends to include chemical, biological, and health-focused pharmaceuticals. These diverse medications address a broad spectrum of medical needs, providing solutions in areas such as pediatrics, gynecology, digestive system ailments, respiratory issues including the common cold, conditions related to rheumatism and bone health, and cardiovascular and cerebrovascular disorders. The company's goods are sold under its established brands, "Sunflower" and "Little Sunflower." With its headquarters located in Harbin, China, Sunflower Pharmaceutical Group was founded in 2005.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 002737.SZ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
